Magasan differenciált pajzsmirigyrák miatt mütött betegek követése thyreoglobulin szint meghatározással.

Translated title of the contribution: Follow up of thyroglobulin levels in patients with surgically treated, highly differentiated thyroid cancer

J. Szántó, B. Vincze, I. Sinkovits, Z. Karika, K. Daubner, I. Péter, I. Kazatsay, S. Eckhardt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The highly differentiated thyroid tumours account for 0.80 percent of all human malignancies. The papillary and follicular tumour tissues of this tumour type are relatively benign, hormone dependent and beside their treatment specificity they secrete the tumour specific thyreoglobulin. Thus it becomes possible to follow the development of metastases, the effectiveness of therapy applied as well as the history of the disease. The authors studied the change of thyreoglobulin level in 153 patients with highly differentiated thyroid cancer. In 29 of 32 metastatic patients pathologically elevated (70 to 100 ng/ml) thyreoglobulin level was observed. This proves the 91 percent specificity of the method in verified metastatic tumours. Compared to the total body scintigraphy 3 false negative cases were found. The authors establish that, irrespective of the site of metastasis, the thyreoglobulin level is higher in the follicular than in the papillary subtype. It is concluded that the measurement of the serum thyreoglobulin level is a suitable marker of the highly differentiated thyroid cancer since it represents the local recurrence of distant metastases with a significant increase while the therapy-resultant tumour diminution with a marked decrease, respectively.

Original languageHungarian
Pages (from-to)1695-1699
Number of pages5
JournalOrvosi Hetilap
Volume130
Issue number32
Publication statusPublished - Aug 6 1989

Fingerprint

Thyroglobulin
Thyroid Neoplasms
Neoplasms
Neoplasm Metastasis
Radionuclide Imaging
Thyroid Gland
Therapeutics
History
Hormones
Recurrence
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Szántó, J., Vincze, B., Sinkovits, I., Karika, Z., Daubner, K., Péter, I., ... Eckhardt, S. (1989). Magasan differenciált pajzsmirigyrák miatt mütött betegek követése thyreoglobulin szint meghatározással. Orvosi Hetilap, 130(32), 1695-1699.

Magasan differenciált pajzsmirigyrák miatt mütött betegek követése thyreoglobulin szint meghatározással. / Szántó, J.; Vincze, B.; Sinkovits, I.; Karika, Z.; Daubner, K.; Péter, I.; Kazatsay, I.; Eckhardt, S.

In: Orvosi Hetilap, Vol. 130, No. 32, 06.08.1989, p. 1695-1699.

Research output: Contribution to journalArticle

Szántó, J, Vincze, B, Sinkovits, I, Karika, Z, Daubner, K, Péter, I, Kazatsay, I & Eckhardt, S 1989, 'Magasan differenciált pajzsmirigyrák miatt mütött betegek követése thyreoglobulin szint meghatározással.', Orvosi Hetilap, vol. 130, no. 32, pp. 1695-1699.
Szántó, J. ; Vincze, B. ; Sinkovits, I. ; Karika, Z. ; Daubner, K. ; Péter, I. ; Kazatsay, I. ; Eckhardt, S. / Magasan differenciált pajzsmirigyrák miatt mütött betegek követése thyreoglobulin szint meghatározással. In: Orvosi Hetilap. 1989 ; Vol. 130, No. 32. pp. 1695-1699.
@article{b2f9c60e5bf7440a99bbdbc1ac1c08f1,
title = "Magasan differenci{\'a}lt pajzsmirigyr{\'a}k miatt m{\"u}t{\"o}tt betegek k{\"o}vet{\'e}se thyreoglobulin szint meghat{\'a}roz{\'a}ssal.",
abstract = "The highly differentiated thyroid tumours account for 0.80 percent of all human malignancies. The papillary and follicular tumour tissues of this tumour type are relatively benign, hormone dependent and beside their treatment specificity they secrete the tumour specific thyreoglobulin. Thus it becomes possible to follow the development of metastases, the effectiveness of therapy applied as well as the history of the disease. The authors studied the change of thyreoglobulin level in 153 patients with highly differentiated thyroid cancer. In 29 of 32 metastatic patients pathologically elevated (70 to 100 ng/ml) thyreoglobulin level was observed. This proves the 91 percent specificity of the method in verified metastatic tumours. Compared to the total body scintigraphy 3 false negative cases were found. The authors establish that, irrespective of the site of metastasis, the thyreoglobulin level is higher in the follicular than in the papillary subtype. It is concluded that the measurement of the serum thyreoglobulin level is a suitable marker of the highly differentiated thyroid cancer since it represents the local recurrence of distant metastases with a significant increase while the therapy-resultant tumour diminution with a marked decrease, respectively.",
author = "J. Sz{\'a}nt{\'o} and B. Vincze and I. Sinkovits and Z. Karika and K. Daubner and I. P{\'e}ter and I. Kazatsay and S. Eckhardt",
year = "1989",
month = "8",
day = "6",
language = "Hungarian",
volume = "130",
pages = "1695--1699",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "32",

}

TY - JOUR

T1 - Magasan differenciált pajzsmirigyrák miatt mütött betegek követése thyreoglobulin szint meghatározással.

AU - Szántó, J.

AU - Vincze, B.

AU - Sinkovits, I.

AU - Karika, Z.

AU - Daubner, K.

AU - Péter, I.

AU - Kazatsay, I.

AU - Eckhardt, S.

PY - 1989/8/6

Y1 - 1989/8/6

N2 - The highly differentiated thyroid tumours account for 0.80 percent of all human malignancies. The papillary and follicular tumour tissues of this tumour type are relatively benign, hormone dependent and beside their treatment specificity they secrete the tumour specific thyreoglobulin. Thus it becomes possible to follow the development of metastases, the effectiveness of therapy applied as well as the history of the disease. The authors studied the change of thyreoglobulin level in 153 patients with highly differentiated thyroid cancer. In 29 of 32 metastatic patients pathologically elevated (70 to 100 ng/ml) thyreoglobulin level was observed. This proves the 91 percent specificity of the method in verified metastatic tumours. Compared to the total body scintigraphy 3 false negative cases were found. The authors establish that, irrespective of the site of metastasis, the thyreoglobulin level is higher in the follicular than in the papillary subtype. It is concluded that the measurement of the serum thyreoglobulin level is a suitable marker of the highly differentiated thyroid cancer since it represents the local recurrence of distant metastases with a significant increase while the therapy-resultant tumour diminution with a marked decrease, respectively.

AB - The highly differentiated thyroid tumours account for 0.80 percent of all human malignancies. The papillary and follicular tumour tissues of this tumour type are relatively benign, hormone dependent and beside their treatment specificity they secrete the tumour specific thyreoglobulin. Thus it becomes possible to follow the development of metastases, the effectiveness of therapy applied as well as the history of the disease. The authors studied the change of thyreoglobulin level in 153 patients with highly differentiated thyroid cancer. In 29 of 32 metastatic patients pathologically elevated (70 to 100 ng/ml) thyreoglobulin level was observed. This proves the 91 percent specificity of the method in verified metastatic tumours. Compared to the total body scintigraphy 3 false negative cases were found. The authors establish that, irrespective of the site of metastasis, the thyreoglobulin level is higher in the follicular than in the papillary subtype. It is concluded that the measurement of the serum thyreoglobulin level is a suitable marker of the highly differentiated thyroid cancer since it represents the local recurrence of distant metastases with a significant increase while the therapy-resultant tumour diminution with a marked decrease, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0024963169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024963169&partnerID=8YFLogxK

M3 - Article

C2 - 2780041

AN - SCOPUS:0024963169

VL - 130

SP - 1695

EP - 1699

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 32

ER -